Posts by odiadmin

Cease & Desist notice issued to owners of a Colorado-based website, www.pingueculaeyedrops.com which was infringing Ocular Discovery’s US patents by offering dipyridamole-containing eye drops. The infringers have ceased sales of their infringing product and transferred ownership of their domains to Ocular Discovery Ltd.

Fifth patent allowance issued in the United States, toward the use of topical dipyridamole for the treatment of melanocytic nevus, cataracts, and ocular melanoma.

Ocular Discovery launches novel research partnership with India’s leading eye care hospital, the Dr. R.P Centre for ophthalmic sciences, to investigate the mechanism of action of Dipyridamole in Ocular Surface Disorders. To view the official press release.

Fourth patent allowance issued in the United States, the for the use of dipyridamole in the following indications: keratitis, corneal abrasions, and corneal ulcers

Patient recruitment complete in India for trial exploring the use and effectiveness of Dipyridamole eye drops for the symptomatic treatment of Pterygium. Trial completion expected by May 2019

Patent allowance issued in China for the indications of Dry Eye Disease, Sjogren’s Syndrome, Pterygium,  Pinguecula, and Corneal Neovascularization

Third patent allowance issued in the United States for the indication of Conjunctivitis

Patent allowance issued in Australia for the indication of Lacrimal and Anterior Eye Segment Disorders

Preclinical experiments support the anti-angiogenic effects of Ocular Discovery’s Dipyridamole drops

Second patent allowance issued in the USA for the treatment of Pterygium, Pinguecula, and Corneal Neovascularization